News & Events
Fibralign Announces Start of European Lymphedema Prevention Clinical Study
Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first...
Fibralign Announces CE Mark Approval for BioBridge®
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
Fibralign Announces Strategic Partnership with Terumo
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...
Fibralign and its research collaborators have made over 50 presentations related to BioBridge and Nanoweave scientific findings at international leading medical research conferences over the previous two years.
While these conferences have largely paused during 2020 due to the pandemic, we will post upcoming presentations when these conferences return to schedule.